In addition to a number of products routinely employed for anesthetic procedures in hospitals, Cristália offers unique products with groundbreaking substances designed with the purpose of providing higher therapeutic effect at affordable prices. Currently, Cristália products are found in more than 95% of Brazilian hospitals.
Cristália Laboratories is now the first in the ranking of anesthetics and narcoanalgesics suppliers for Brazilian hospitals. About 3,600 Hospitals and Clinics, both private and public, are visited every month by our sales representatives.
Cristália markets the most comprehensive range of anesthetics and adjuvant drugs for anesthetic procedures throughout the country. Its portfolio includes almost all locoregional anesthesia and adjuvant molecules, as well as neuromuscular blockers employed in general anesthesia, either administered as inhaled products, for IV injection, and/or balanced solutions.
The narcoanalgesics line is the most comprehensive one in Brazilian market, both as injectables, oral administration, or long-acting products. Thus, Cristália offers palliative care for pre-, intra-, and post-operative pain, as well as for patients suffering from chronic pain.
Cristália was a pioneer in introducing morphine drugs into local marketplace. In addition, the company provides the most comprehensive line of products for mental health to public and private psychiatric hospitals.
With products combining high quality and affordable prices, Cristália is a key supplier of antiretrovirals for the Ministry of Health’s anti-AIDS program. A partnership that provides higher therapy effects with savings for the whole Brazilian healthcare chain.
Among the key exclusive products provided by Cristália that are protected by patents, the following are included:
Alimax (sodium heparin)
Alimax&is a drug designed to treat burns. It contains heparin as active substance. The pharmaceutical formulation supplied as sterile aqueous solution, which provides better adhesion on injuries, was patented in the United States.
Alimax is supplied as vials with a sprinkler device enabling that the right dose is applied onto the injury surface.
AZICIN (azithromycin dihydrate)
Azicin is an antibiotic agent that works by preventing azithromycin-sensitive bacteria from secreting proteins, which are the basis for their growth and reproduction. The product is indicated for patients who need early intravenous therapy for the following conditions: Community-acquired pneumonia caused by azithromycin-susceptible organisms, including infections caused by Legionella pneumophila, and pelvic inflammatory disease caused by azithromycin-susceptible organisms.
Brevibloc (Esmolol hydrochloride)
Brevibloc is a selective beta-1 adrenoceptor antagonist (cardioselective) with a very short-lasting action. It is indicated for Supraventricular Tachycardia and Noncompensatory Sinusal Tachycardia, when, at physician's discretion, rapid heart rates requires specific intervention and in tachycardia and/or intra- and post-operative high pressure.
Clonidin (Clonidine Hydrochloride)
Clonidin (Clonidine hydrochloride) / The product Clonidin solution for injection can be used as pain killer, having synergic activity with lipophilic opioids, morphine, and topic anesthetics. It works by providing hemodynamic stabilization.
Dantrolen - (sodium dantrolene)
is a medicine. While using it, please, refrain from driving vehicles or operating machines, since your level of attention and dexterity may be temporarily impaired. .
Until 1996, Brazil didn't have sodium dantrolene available for the management of Malignant Hyperthermia Syndrome, which, while rare, has a high mortality rate. That same year, Cristália donated the first imported dantrolene kits for one of SBA's (Brazilian Society of Anesthesiology) regional offices, and then started to market the product. But, even by giving up any potential profits from its sale, the company couldn't make the product available for an affordable price.
As a result of that, Cristália's RD&I (Research, Development & Innovation) department developed and started to synthesize the compound, warranting its supply to Brazilian market at a significantly lower price. That enabled Brazilian hospitals to have this drug available at an affordable price, and no longer dependant on foreign production.
DEX® is a relatively selective alpha-2 adrenergic receptor agonist intended to cause sedation in patients (with and without mechanical ventilation) during intensive care procedures (at Intensive Care Units, operating theaters, or diagnostic tests).
Difenidrin(Diphenhydramine hydrochloride) /
Diphenhydramine hydrochloride solution for injection is a first-generation H1 antihistamine causing anticholinergic and sedative side effects, being indicated for prophylaxis and treatment of allergic responses to infused drugs, particularly cancer medications, blood products and diagnostic reagents, as well as for treatment and prophylaxis of anaphylactic reactions as an adjunct to epinephrine.
Ketamin - (dextroketamine hydrochloride)
Ketamine is an endovenous anesthetic agent developed in the 1950's. This is a racemic compound where one of its enantiomers is responsible for causing adverse effects, and, therefore, leading to its reduced clinical use. So, Cristália developed Ketamin – dextroketamine hydrochloride, a product formulated with the enantiomer dextrogire, therefore delivering increased effectiveness, and enabling the use of lower doses, therefore reducing the adverse effects seen with original formulas. That discovery led to another key patent - for dextroketamine –currently filed in the United States, Europe, and Argentina.
LYNOZ® is a synthesized antibacterial agent belonging to a new class of antibiotics – the oxazolidinones – with in vitro activity against aerobic Gram-positive bacteria, some Gram-negative bacteria, and anaerobic microorganisms.
Intended for use in suspected or confirmed cases of infections caused by susceptible bacteria in:
• Hospital-acquired (including those associated to mechanical ventilation) or community-acquired pneumonia;
• Complicated and uncomplicated skin or soft parts infections (including diabetic foot ulcers without concurrent osteomyelitis);
• Enterococcal infections, including those caused by Enterococcus faecium and Enterococcus faecalis strains resistant to vancomycin. This drug has activity only against Gram-positive bacteria.
MOXICRIS (moxifloxacin hydrochloride)
Moxifloxacin is a broad-spectrum antibacterial agent with bactericidal activity and in vitro activity against a wide range of Gram-positive, Gram-negative, and anaerobic microorganisms, and acid-resistant and atypical bacteria. Moxicris solution for infusion is indicated for treating the following bacterial infections caused by susceptible
• community-acquired pneumonia (CAP) including CAP caused by strains resistant to multiple drugs*;
• complicated infections of the skin and adnexa (including diabetic foot infections);
• complicated intra-abdominal infections, including polymicrobial infections, such as abscesses.
Novabupi ( (levobupivacaine hydrochloride) )
Novabupiis a locoregional anesthetic developed in collaboration with University of São Paulo (USP) from bupivacaine, in an enantiomeric mixture among its enantiomers levogire and dextrogire. Its discovery enabled a safer drug, without reducing its clinical effectiveness. The technology behind the product was patented in the USA, Europe, and, more recently, in Brazil. The product is supplied as Novabupi Isobaric and Novabupi Solution for Injection.
The active substance included in Remifas® is remifentanil, which belongs to a group of drugs named opioid receptor agonists. Those drugs can provide anesthesia, as well as pain relief and sedation during surgical procedures. Remifentanil has a fast onset of action, but doesn't last long.
Remifas® is a drug prescribed to produce or maintain anesthesia during surgeries, including heart surgeries, and for relieving immediate post-operative pain.
Remifas® is also indicated as a pain killer and sedative agent in mechanically ventilated patients (i.e., those relying on machines to breathe) in intensive care units (ICU).
SEVOCRIS® IS A MEDICINE. WHILE USING IT, PLEASE, REFRAIN FROM DRIVING VEHICLES OR OPERATING MACHINES, BECAUSE YOUR LEVEL OF ATTENTION AND DEXTERITY MAY BE TEMPORARILY IMPAIRED.
Sevocris is an important inhaled anesthetic, and contains sevoflurane as active substance. Cristália was the second pharmaceutical company in the world to develop this product, and its increased offer in the marketplace caused a drop on this drug's price, and an increased population's access to a cutting-edge anesthetic agent.
Cristália has already been granted with a patent for this product formula in Europe, Mexico, Japan, China, United States, and Hong Kong.
Tridil is a titratable antihypertensive drug, causing vasodilatation of arterial and venous smooth muscles. Tridil works by redistributing the blood flow to the heart in case of partial occlusion of coronary blood flow. It is intended for treating pre-operative hypertension, for congestive heart failure control, for treating acute myocardial infarction and angina pectoris, as well as for inducing intraoperative hypotension.
VORI FOR INJECTION (Voriconazole)
VORI is a synthetic second-generation antifungal agent structurally derived from fluconazole. It has a broad spectrum of activity against a wide variety of molds and yeasts. Indications: VORI is a broad-spectrum triazole antifungal agent, prescribed in the following situations:
• For treating invasive aspergillosis.
• For treating serious invasive Candida infections, including candidemia and esophageal candidiasis (including C.krusei).
• For treating serious fungal infections by Scedosporium spp. and Fusarium spp.
• VORI should be particularly administered in patients with progressive, life-threatening infections.
• It is supplied as tablets and as solution for injection.
NEW CRISTÁLIA PACKAGING
Added safety for healthcare organizations, doctors, and patients
Constantly collaborating with major healthcare organizations and with the clinicians, Cristália brings another innovation and is positioned a step ahead of the competition by introducing in its packaging line an unparalleled security standard in Brazilian pharmaceutical industry.
After reviewing the needs signaled by hospitals, doctors, pharmacists, and nurses – and, by heavily investing with financial resources – Cristália has developed, using a proprietary technology, THREE NEW SECURITY PROCESSES FOR 100% OF ITS PACKAGING LINE, INCLUIDING PRIMARY AND SECONDARY PACKAGES.
NEW COLOR CODING FOR ADDED SECURITY
Different color-coded labels for vials and ampoules of products belonging to the same therapeutic class.
Boxes in different colors matching their respective strengths: ranging from green (lower strengths), through blue and red (medium strengths) to black (higher strengths) in primary packages (labels).
NEW SECURITY LETTERS
Following the recommendations of global organizations, such as "The Joint Commission" and the "Food and Drug Administration – FDA", Cristália is now distinguishing its primary and secondary packages by printing the first three letters of all company's brands in upper case.